These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Single dose comparison of the relative bioavailability of phenytoin suspension and extended capsules. Fitzsimmons WE; Garnett WR; Comstock TJ; Pellock JM Epilepsia; 1986; 27(4):464-8. PubMed ID: 3720707 [TBL] [Abstract][Full Text] [Related]
6. When do differences in dissolution profiles predict clinical problems? Ngo SN J Clin Pharm Ther; 2007 Apr; 32(2):111-2. PubMed ID: 17381660 [No Abstract] [Full Text] [Related]
7. Generic substitution resulting in toxicity. Finestone AJ; Williams FF Pa Med; 1985 Dec; 88(12):34. PubMed ID: 4080394 [No Abstract] [Full Text] [Related]
8. Phenytoin II: in vitro-in vivo bioequivalence standard for 100-mg phenytoin sodium capsules. Shah VP; Prasad VK; Freeman C; Skelly JP; Cabana BE J Pharm Sci; 1983 Mar; 72(3):309-10. PubMed ID: 6842384 [TBL] [Abstract][Full Text] [Related]
9. Status of generic substitution: problematic drug classes reviewed. Ross MB Hosp Formul; 1989 Aug; 24(8):441-4, 447-9. PubMed ID: 10294356 [TBL] [Abstract][Full Text] [Related]
10. What are narrow therapeutic index drugs? Levy G Clin Pharmacol Ther; 1998 May; 63(5):501-5. PubMed ID: 9630822 [No Abstract] [Full Text] [Related]
11. FDA problems with medications in the marketplace: I. Archambault GF Hosp Formul; 1976 Apr; 11(4):224. PubMed ID: 1037449 [No Abstract] [Full Text] [Related]
12. What's in a name? Generic vs brand name drugs. Levin AA Health PAC Bull; 1986 Jun; 16(5):37, 39. PubMed ID: 10276741 [No Abstract] [Full Text] [Related]
13. Bioavailability and dissolution of proprietary and generic formulations of phenytoin. Soryal I; Richens A J Neurol Neurosurg Psychiatry; 1992 Aug; 55(8):688-91. PubMed ID: 1527539 [TBL] [Abstract][Full Text] [Related]
14. Comparison on bioequivalence of four phenytoin preparations in patients with multiple-dose treatment. Tsai JJ; Lai ML; Yang YH; Huang JD J Clin Pharmacol; 1992 Mar; 32(3):272-6. PubMed ID: 1564132 [TBL] [Abstract][Full Text] [Related]
15. Prescription drug products that require patient package inserts; ampicillin and phenytoin--Food and Drug Administration. Final rule. Fed Regist; 1981 Jan; 46(1):28. PubMed ID: 10249520 [TBL] [Abstract][Full Text] [Related]
16. Nonequivalence of phenytoin capsules and tablets. Raebel MA N Engl J Med; 1983 Oct; 309(15):925. PubMed ID: 6888489 [No Abstract] [Full Text] [Related]
17. Generic vs. brand name drugs--defining and enforcing standards. Lasagna LC Internist; 1979 May; 20(4):11, 13. PubMed ID: 10316827 [No Abstract] [Full Text] [Related]
18. Generic drug substitution. Rogowski A; Lemay V Med Health R I; 2001 Jul; 84(7):241-4. PubMed ID: 11482281 [No Abstract] [Full Text] [Related]
19. Generic vs. brand name drugs--quality, not cost, is key issue. Stetler CJ Internist; 1979 May; 20(4):9-10, 12. PubMed ID: 10242133 [No Abstract] [Full Text] [Related]
20. Bioavailability and bioequivalence requirements: abbreviated applications. Final Rule. Food and Drug Administration, HHS Fed Regist; 2002 Dec; 67(244):77668-75. PubMed ID: 12492102 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]